Industry Briefs: July 9, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AstraZeneca has completed the previously announced sale of the assets of its subsidiary, Aptium Oncology. Read More
Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and ADC Therapeutics Sarl (ADCT) have signed agreements to develop antibody drug conjugates using CRT’s antibodies and peptides, and ADCT’s linker chemistries and proprietary pyrrolobenzodiazepines technology. Read More
The CureBeta R&D collaboration between Evotec and Harvard University has entered into a strategic alliance with Janssen Pharmaceuticals. Read More
Hal Allergy has expanded its GMP contract manufacturing activities for clinical-batch supply of both recombinant and viral products. Read More
Prokarium, a spin-out company of Cobra Biologics, has acquired oral-vaccine technology from Emergent BioSolutions. Read More
Sanofi has agreed to divest its 19.3% stake in the Yves Rocher Group. Read More
Spectrum Pharmaceuticals has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics for $1.82 per share in cash. Read More
People News
Affymax has named Michael Holfinger vice-president of manufacturing and CMC development. Read More
Arena Pharmaceuticals has appointed Craig M. Audet to executive officer as senior vice-president, operations, and head of global regulatory affairs. Read More
Chiral Technologies has appointed Jauh-Tzuoh Lee as technology manager. Read More
Ricerca Biosciences named G. Lynn Miesel technical director. Read More
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
